Translate Bio Announces Proposed Public Offering of Common Stock
September 17 2019 - 4:01PM
Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA
(mRNA) therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that it has commenced an
underwritten public offering of $90 million of its common stock.
Translate Bio also intends to grant the underwriters a 30-day
option to purchase up to an additional 15% of the shares of common
stock sold in the public offering. All of the shares are being
offered by Translate Bio.
Citigroup, Jefferies and SVB Leerink are acting as joint
book-running managers for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The shares are being offered by Translate Bio pursuant to an
effective shelf registration statement that was filed with the
Securities and Exchange Commission (SEC) on July 3, 2019 and
declared effective by the SEC on July 19, 2019.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering is expected to be filed with
the SEC and, when filed, copies of the preliminary prospectus
supplement relating to the offering may be obtained for free by
visiting the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may also be obtained by contacting: Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: 1-800-831-9146; Jefferies LLC,
Attention: Equity Syndicate Prospectus Departments, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by phone at (877) 821-7388,
or by email at Prospectus_Department@Jefferies.com; or SVB Leerink
LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132,
or by email at syndicate@svbleerink.com. The final terms of the
offering will be disclosed in a final prospectus supplement to be
filed with the SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Translate BioTranslate Bio is a
clinical-stage mRNA therapeutics company developing a new class of
potentially transformative medicines to treat diseases caused by
protein or gene dysfunction. Translate Bio’s mRNA therapeutic
platform (MRT platform) is designed to develop product candidates
that deliver mRNA carrying instructions to produce intracellular,
transmembrane and secreted proteins for therapeutic benefit.
Translate Bio is primarily focused on applying its MRT platform to
pulmonary diseases caused by insufficient protein production or
where production of proteins can modify disease. Translate Bio also
believes that its technology is applicable to a broad range of
diseases, including diseases that affect the liver, eye and the
central nervous system. Additionally, the MRT platform may be
applied to various classes of treatments, such as therapeutic
antibodies or vaccines in areas such as infectious disease and
oncology. Translate Bio’s lead program is being developed as a
treatment for cystic fibrosis (CF) and is in an ongoing Phase 1/2
clinical trial.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to, those
regarding Translate Bio’s plans to consummate its proposed public
offering. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from current expectations
and beliefs, including but not limited to: market and other
financing conditions; Translate Bio’s ability to advance the
development of its platform and programs under the timelines it
projects; demonstrate the requisite safety and efficacy of its
product candidates and replicate in later-stage clinical trials any
positive findings from preclinical studies; the content and timing
of decisions made by the U.S. Food and Drug Administration, other
regulatory authorities and investigational review boards at
clinical trial sites, including as it relates to ongoing and
planned clinical trials; Translate Bio’s ability to obtain,
maintain and enforce necessary patent and other intellectual
property protection; the availability of significant cash required
to fund operations; competitive factors; general economic and
market conditions and other important risk factors set forth under
the caption “Risk Factors” in the preliminary prospectus to be
filed with the SEC, in Translate Bio’s Quarterly Report on Form
10-Q for the quarterly period ended June 30, 2019 and in any other
subsequent filings made with the SEC by Translate Bio. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Translate Bio specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
|
|
|
Contacts for Translate
Bio |
|
|
|
|
|
Investors |
|
Media |
Teri Dahlman |
|
Maura Gavaghan |
tdahlman@translate.bio |
|
mgavaghan@translate.bio |
857-242-7792 |
|
857-242-7789 |
|
|
|
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024